Literature DB >> 18759295

The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus.

Silvia N Kariuki1, Mary K Crow, Timothy B Niewold.   

Abstract

OBJECTIVE: The C1858T polymorphism in PTPN22 has been associated with the risk of systemic lupus erythematosus (SLE) as well as multiple other autoimmune diseases. We have previously shown that high serum interferon-alpha (IFNalpha) activity is a heritable risk factor for SLE. The aim of this study was to determine whether the PTPN22 risk variant may shift serum cytokine profiles to higher IFNalpha activity, resulting in risk of disease.
METHODS: IFNalpha was measured in 143 patients with SLE, using a functional reporter cell assay, and tumor necrosis factor alpha (TNFalpha) was measured by enzyme-linked immunosorbent assay. The rs2476601 single-nucleotide polymorphism in PTPN22 (C1858T) was genotyped in the same patients. Patients were grouped, using a clustering algorithm, into 4 cytokine groups (IFNalpha predominant, IFNalpha and TNFalpha correlated, TNFalpha predominant, and both IFNalpha and TNFalpha low).
RESULTS: SLE patients carrying the risk allele of PTPN22 had higher serum IFNalpha activity than patients lacking the risk allele (P = 0.027). TNFalpha levels were lower in carriers of the risk allele (P = 0.030), and the risk allele was more common in patients in the IFNalpha-predominant and IFNalpha and TNFalpha-correlated groups as compared with patients in the TNFalpha-predominant and both IFNalpha and TNFalpha-low groups (P = 0.001). Twenty-five percent of male patients carried the risk allele, compared with 10% of female patients (P = 0.024); however, cytokine skewing was similar in both sexes.
CONCLUSION: The autoimmune disease risk allele of PTPN22 is associated with skewing of serum cytokine profiles toward higher IFNalpha activity and lower TNFalpha levels in vivo in patients with SLE. This serum cytokine pattern may be relevant in other autoimmune diseases associated with the PTPN22 risk allele.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759295      PMCID: PMC2621106          DOI: 10.1002/art.23728

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  14 in total

Review 1.  Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy.

Authors:  Y Ioannou; D A Isenberg
Journal:  Arthritis Rheum       Date:  2000-07

2.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases.

Authors:  A Karolina Palucka; Jean-Philippe Blanck; Lynda Bennett; Virginia Pascual; Jacques Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

3.  Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

Authors:  P Blanco; A K Palucka; M Gill; V Pascual; J Banchereau
Journal:  Science       Date:  2001-11-16       Impact factor: 47.728

Review 4.  The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis.

Authors:  Y H Lee; Y H Rho; S J Choi; J D Ji; G G Song; S K Nath; J B Harley
Journal:  Rheumatology (Oxford)       Date:  2006-06-07       Impact factor: 7.580

5.  Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease.

Authors:  Hui Wu; Rita M Cantor; Deborah S Cunninghame Graham; Cecilia M Lingren; Lisa Farwell; Philip L De Jager; Nunzio Bottini; Jennifer M Grossman; Daniel J Wallace; Bevra H Hahn; Heikki Julkunen; Lee A Hebert; Brad H Rovin; Dan J Birmingham; John D Rioux; C Yung Yu; Juha Kere; Timothy J Vyse; Betty P Tsao
Journal:  Arthritis Rheum       Date:  2005-08

6.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

Review 7.  Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity.

Authors:  D Devendra; G S Eisenbarth
Journal:  Clin Immunol       Date:  2004-06       Impact factor: 3.969

8.  High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

Authors:  T B Niewold; J Hua; T J A Lehman; J B Harley; M K Crow
Journal:  Genes Immun       Date:  2007-06-21       Impact factor: 2.676

Review 9.  Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C.

Authors:  Timothy B Niewold; William I Swedler
Journal:  Clin Rheumatol       Date:  2004-11-24       Impact factor: 3.650

10.  Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients.

Authors:  Matthias Pierer; Sylke Kaltenhäuser; Sybille Arnold; Matthias Wahle; Christoph Baerwald; Holm Häntzschel; Ulf Wagner
Journal:  Arthritis Res Ther       Date:  2006-04-24       Impact factor: 5.156

View more
  55 in total

1.  The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.

Authors:  Sandra Agik; Beverly S Franek; Akaash A Kumar; Marissa Kumabe; Tammy O Utset; Rachel A Mikolaitis; Meenakshi Jolly; Timothy B Niewold
Journal:  J Rheumatol       Date:  2011-11-01       Impact factor: 4.666

2.  Systemic sclerosis and lupus: points in an interferon-mediated continuum.

Authors:  Shervin Assassi; Maureen D Mayes; Frank C Arnett; Pravitt Gourh; Sandeep K Agarwal; Terry A McNearney; Damien Chaussabel; Nancy Oommen; Michael Fischbach; Kairav R Shah; Julio Charles; Virginia Pascual; John D Reveille; Filemon K Tan
Journal:  Arthritis Rheum       Date:  2010-02

3.  Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort.

Authors:  Clio P Mavragani; Dan T La; William Stohl; Mary K Crow
Journal:  Arthritis Rheum       Date:  2010-02

4.  Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus.

Authors:  Corinna E Weckerle; Beverly S Franek; Jennifer A Kelly; Marissa Kumabe; Rachel A Mikolaitis; Stephanie L Green; Tammy O Utset; Meenakshi Jolly; Judith A James; John B Harley; Timothy B Niewold
Journal:  Arthritis Rheum       Date:  2011-04

Review 5.  The Contribution of PTPN22 to Rheumatic Disease.

Authors:  Tomas Mustelin; Nunzio Bottini; Stephanie M Stanford
Journal:  Arthritis Rheumatol       Date:  2019-03-02       Impact factor: 10.995

Review 6.  Genetic regulation of serum cytokines in systemic lupus erythematosus.

Authors:  Silvia N Kariuki; Timothy B Niewold
Journal:  Transl Res       Date:  2009-09-25       Impact factor: 7.012

7.  Interferon-alpha: a therapeutic target in systemic lupus erythematosus.

Authors:  Mary K Crow
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

Review 8.  Type I interferon in rheumatic diseases.

Authors:  Theresa L Wampler Muskardin; Timothy B Niewold
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 9.  Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.

Authors:  Tineke Cantaert; Dominique Baeten; Paul P Tak; Lisa G M van Baarsen
Journal:  Arthritis Res Ther       Date:  2010-10-28       Impact factor: 5.156

10.  The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus.

Authors:  Ilan Ben-Zvi; Cynthia Aranow; Meggan Mackay; Anfisa Stanevsky; Diane L Kamen; L Manuela Marinescu; Christopher E Collins; Gary S Gilkeson; Betty Diamond; John A Hardin
Journal:  PLoS One       Date:  2010-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.